Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

NCT03071874 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Meningioma

Interventions

DRUG: AZD2014

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]